

CURRICULUM VITAE**Name:** Margaret Ann Tempero**Position:** Professor of Medicine, Step 5
Department of Medicine
School of Medicine**Address:** UCSF Helen Diller Family Comprehensive Cancer Center
1600 Divisadero Street, #B726 Box 1770
University of California San Francisco
San Francisco, CA 94115

Voice: (415) 885-3846

FAX: (415) 353-9636

email: mtempero@medicine.ucsf.eduwww: http://cancer.ucsf.edu/people/tempero_margaret.php**EDUCATION:**

1967-69	Creighton University	B.S.	Medical Technology
1972-74	University of Nebraska	M.S.	Clinical Pathology
1974-77	University of Nebraska	M.D.	Medicine
1977-80	University of Nebraska	Resident	Internal Medicine
1980-82	University of Nebraska	Fellow	Medical Oncology/Hematology
1981-81	Memorial Sloan-Kettering		Visiting Research Fellow

LICENSES, CERTIFICATION:

2000	California # [REDACTED] (b) (6)
1978	Nebraska License # [REDACTED] (b) (6)
1978	National Board Certification
1980	Diplomate, American Board of Internal Medicine
1983	Diplomate, Medical Oncology, ABIM
1984	Diplomate, Hematology ABIM

PRINCIPAL POSITIONS HELD:

1983-87	University of Nebraska	Assistant Professor	Medicine
1987-94	University of Nebraska	Associate Professor	Medicine
1994-99	University of Nebraska	Professor	Medicine
2000-present	University of California San Francisco	Professor	Medicine

OTHER POSITIONS HELD CONCURRENTLY:

1983-99	Omaha V. A. Medical Center	Chief of Oncology and Hematology
9/96-2/99	UNMC/Eppley Cancer Center	Interim Director
1995-99	UNMC/Eppley Cancer Center	Deputy Director
1985-87	Eppley Institute for Cancer Research	Assistant Professor (Courtesy)
1987-94	Eppley Institute for Cancer Research	Associate Professor (Courtesy)
1994-present	Eppley Institute for Cancer Research	Professor (Courtesy)
2000-2007	University of California, San Francisco	Chief, Division of Medical Oncology
2000-2009	UCSF Comprehensive Cancer Center	Deputy Director, Director of Clinical Science
2009-present	UCSF Comprehensive Cancer Center	Deputy Director, Director of Research Programs

HONORS AND AWARDS:

1977	Highest Achievement in Academic Obstetrics, (Medical school)
1979-80	Chief Medicine Resident, Clarkson Hospital
1984-86	American Cancer Society Junior Clinical Faculty Fellowship
1987	American College of Physicians, Fellow
1987	Appointed Distinguished Cancer Research Professor, University of Nebraska,
1992	Good Housekeeping's "400 Best Cancer Doctors in America" List
1997-99	UNMC Distinguished Cancer Research Professor, Endowed Chair
1996, 98, 03	Best Doctors in America
1999	Good Housekeeping's "318 Top Cancer Specialists for Women" List
2000	Thomas Schafer Annual Endowed Lectureship, Georgetown University
2000-present	Doris and Don Fisher Distinguished Professor in Clinical Research
2001	Co-Chair, NIH, Progress Review Group in Pancreatic Cancer
2002-present	Castle Connolly Guides: America's Top Doctors
2003	Norbert and Suzanne Schnog Lecturer, Yale Cancer Center
2003	McPeak Lecturer, Memorial Sloan Kettering
2003	Medical Visionary Award, Pancreatic Cancer Action Network
2004	Brigid G. Leventhal, M.D. Memorial Lectureship
2008	Honorary Professorship, Peking Union Medical College
2010	Claude Jacquillat Award for Achievement in Clinical Oncology, Pitié-Salpêtrière Hospital, Paris, France
2010	Statesman Award, American Society of Clinical Oncology (ASCO)

KEYWORDS/AREAS OF INTEREST:

Cancer, pancreas, pancreatic adenocarcinoma, gastrointestinal cancers, clinical trials, biomarkers, CA 19-9, gemcitabine, antibodies, immunotherapy, radioimmunoconjugate, quality of life, practice guidelines

PROFESSIONAL ACTIVITIES

CLINICAL

Gastrointestinal Cancer Clinic, UCSF Comprehensive Cancer Center: I have attended in this clinic for 12 months of the year for half a day per week for the past ten years.

Attending, Hematology/Oncology Service, SFVAMC: I attend four weeks of the year on this service, supervising house staff, fellows and medical students.

SUMMARY OF CLINICAL ACTIVITIES

I have a small ambulatory clinic 1/2 day per week focused on pancreatic cancer patients and I attend and teach at the VA four weeks each year.

PROFESSIONAL ORGANIZATIONS

Memberships

2000 – Present	American Association for Cancer Research
2000 – Present	American College of Physicians
2000 – Present	American Gastroenterological Association
2000 – Present	American Pancreatic Association
2000 – Present	American Society for Clinical Oncology
2000 – Present	American Society of Hematology
2000 – Present	Association of Northern California Oncologists
2000 – Present	International Association of Pancreatology

SERVICE TO PROFESSIONAL ORGANIZATIONS

American Association for Cancer Research (AACR)

1993	State Legislative Committee, Member
1994-95	Travel Awards Committee, Member
1994-95	Rosenthal Award Subcommittee, Member
1994-95	Welcome Oncology Clinical Research Scholar Awards Committee, Member
1995-96	Special Memberships Committee, Member
1996-97	Special Memberships Committee, Chairperson
1998-99	Public Issues Committee, Member
1998-02	ASCO/AACR Program Committee Joint Workshop “Methods in Clinical Cancer Research”, 1998, 1999-Deputy Director; 2000-2002, Co-Director
1999-02	Special Conferences Committee, Member
1999-03	Scientific Program Committee, Member
2001-02	Local Arrangements Committee for the 2002 meeting, Member
2004	AACR/Lustgarten Conference on Pancreatic Cancer, Chairperson
2009	Pancreatic Cancer Research Grants Scientific Review Committee, Chairperson
2010	Pancreatic Cancer Research Grants Scientific Review Committee, Member
2010-2011	Women in Cancer Research Charlotte Friend Memorial Lectureship Committee, Member

American College of Physicians ACP)

1996-97	Publication Policy Committee, Member
1997-98	Publications Committee, Member

American Society of Clinical Oncology (ASCO)

1989-91 Cancer Education/Training Committee, Member
1992-94 Special Awards Committee, Member
1992-96 Program Committee, Member
1995-96 Gastrointestinal Cancer Subcommittee, Program Committee, Chairperson
1996-97 Annual Meeting Program Committee, Chairperson
1997-99 American Joint Committee on Cancer, Sponsoring Member representing ASCO
1997-00 American College of Surgeons, Commission on Cancer, Committee on Standards, ASCO Liaison, Member
1998 ASCO and Oncology Nursing Society Task Force, Chairperson
1998-00 ASCO/AACR Program Committee Joint Workshop “Methods in Clinical Cancer Research”, Deputy Director; 1998-01, Member; 2000-02, Co-Director Board of Directors
1999 Speakers Bureau Program, Member
2001-present Task Force on Associate/Junior Active Members, Leader
2001-03 Program Committee, Member
2001-04 Special Awards Selection Committee, Member
2002-03 Gastrointestinal Cancer Subcommittee, Program Committee, Chairperson
2002-03 Board Strategic Planning Committee, Member
2002-03 President-elect
2003-04 President
2004-06 Foundation Board of Directors, Member
2008-2010 Special Awards Selection Committee, Member
2009-2011 Cancer Foundation Grants Selection Committee, Member

Association of Northern California Oncologists (ANCO)

2009-2011 Board of Directors, Member

Belgium Foundation Against Cancer

2008 Grant Reviewer
2010 Grant Reviewer

Cell Kinetics Society

1988-89 Nominating Committee, Member

International Association of Pancreatology (IAP)

1998-0 Council Member, 2003-2006

Pancreatic Cancer Action Network (PanCAN)

1999-present Scientific Advisory Board, Member
2008-present Chair, Completely Annotated Pancreas Tumor Repository (CAPTuRe) Project

V Foundation

2010-present Chair, Selection Committee, 2010 Translational Grant

SERVICE TO PROFESSIONAL PUBLICATIONS

EDITORIAL BOARDS:

1991-1997	American Journal of Gastroenterology, Associate Editor
1993-2001	Digestive Diseases
1995-1998	Annals of Internal Medicine
1998-1999	Journal of Clinical Oncology
1998-2001	Oncology
1995-2000	Cancer Research, Associate Editor
1998	Critical Reviews in Oncology/Hematology
1999-2002	Evidence Based Oncology, Associate Editor
2000-2003	American Journal of Medicine, Associate Editor
2001	Clinical Cancer Research, Associate Editor
2001-present	International Journal of Gastrointestinal Cancer
2002	NCCN Journal

Reviewer for: Journal of Oncology Practice, Nature, New England Journal of Medicine, Nature Reviews Cancer, Cancer, Annals of Oncology, Gastroenterology, New England Journal of Medicine, PLoS Medicine, The Journal of the National Comprehensive Cancer Network and the Journal of Gastrointestinal Cancer.

INVITED PRESENTATIONS (invited speaker unless noted otherwise)

INTERNATIONAL

Symposium on Liver Metastases, Leiden, The Netherlands, 1984

Workshop on Detection of Liver Metastases. Symposium on Liver Metastases, Leiden, The Netherlands, 1984

International Society of Preventive Oncology, Copenhagen, Denmark, November 1985

Symposium on the treatment of pancreatic carcinoma with monoclonal antibody CO17-1A, Stockholm, Sweden, August 1987

The 29th Annual Meeting of the Japanese Society of Gastroenterology Symposium in Chuo-ku, Tokyo, Japan, Nara Medical College in Nara, Japan, Kanazawa University School of Medicine in Kanazawa, Japan and The Green Cross Corporation in Osaka, Japan, November 1987

17-1A Club Meeting, Munich, West Germany, March 1989

An Internationally Symposium Sponsored by The Wistar Institute and Holy Cross Hospital, March 1990

5th International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 1990

Kumamoto University, Kumamoto, Japan, August 17, 1990

International Association of Pancreatology 4th Annual Meeting, Nagasaki, Japan, August 1990

The Royal Melbourne Hospital, Victoria, Australia, August 25, 1990; Grand Rounds, St. Vincent's Hospital, Victoria, Australia, September 1990

Department of Surgery, University of Lund, Lund, Sweden, March 25, 1991

Southern Swedish Oncology Society, Lund Sweden, March 26, 1991

Swedish Pancreatic Club, Soderköping, Sweden, March 27, 1991

Symposium on MAb EMD 55 900 in Cancer Therapy, Wiesbaden, Germany, June 1992

International Association of Pancreatology Meeting, Athens, Greece, September 1992

National Cancer Institute Workshop; US-Japan Joint Seminar Gastrointestinal Tumors

Biochemical Modulation and Monoclonal Antibody; Tokyo, Japan, November 1992
 Seminar, Kumamoto University, Kumamoto, Japan, November 1992
 Grand Rounds, Mitsui Ohmuta Hospital, Kumamoto, Japan, November 1992
 Pisa Symposia in Oncology, Breast Cancer: From Biology to Therapy, Pisa, Italy, October 1992
 Eighth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA, March 1993
 Advances in the Diagnosis and Management of Colorectal and Ovarian Cancer Symposium, Puerto Vallarta, Mexico, sponsored by the Alton Ochsner Medical Foundation, New Orleans, LA, April 1993
 Society of Nuclear Medicine's 40th Annual Meeting, Toronto, Ontario, Canada, June 1993
 Centennial Celebration of the Royal Victoria Hospital, Montréal, Québec, Canada, June 1994
 Innovative Therapies in Cancer Treatment, Ravenna, Italy, November 1995
 6th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 1996
 Integrated approach to pancreatic cancer -- A joint Federation of European Cancer Society/American Society of Clinical Oncology Symposium, Ninth Annual European Cancer Conference, Hamburg, Germany, September 1997
 8th International Congress on Anti-Cancer Treatment, Paris, France, February 1998
 International Symposium on Pancreatic Disease: State of the Art and Future Aspects of Research, Munich, Germany, September 1998
 Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, Germany, September 1998
 9th International Congress on Anti-Cancer Treatment, Paris, France, February 1999
 US-Japan Workshop on Clinical Trials, Tokyo, Japan, February 1999
 Grand Rounds, Cross Cancer Institute, Edmonton, Alberta, Canada, September 28, 1999
 9th World Congress of the International Gastro-Surgical Club, Nagasaki, Japan, October 1999
 Molecular Diagnostics for Digestive Malignancy, Session Co-Chair, 9th World Congress of the International Gastro-Surgical Club, Nagasaki, Japan, October 1999
 10th Annual International Congress on Anti-Cancer Treatment, Paris, France, February 2000
 11th Annual International Congress on Anti-Cancer Treatment, Paris, France, February 2001
 Seminar, Himeji National Hospital, Japan, February 2001
 Lecture, Kumamoto National Hospital, Kumamoto, Japan, March 2001
 39th Annual Congress of the Japan Society of Clinical Oncology, Japan, November 2001
 Chinese Anti-Cancer Association (CACA), Beijing, China, June 2002
 Chinese Society of Clinical Oncology (CSCO), Guangzhou, China, June 2002
 European Pancreatic Cancer – Research Cooperative (EPC) Liverpool Meeting, University of Liverpool, England, June 2003
 The European Cancer Conference (ECCO) Annual Conference, Copenhagen, Denmark, September 2003
 13th Annual International Congress on Anti-Cancer Treatment, Paris, France, February 2003.
 World Congress on GI Cancer, Barcelona, June 2004
 ACORD (Australia & Asia Pacific Clinical Oncology Research Development) Workshop, Palm Cove, Australia, August 2004
 ACORD (Australia & Asia Pacific Clinical Oncology Research Development) Workshop, Palm Cove, Australia, August 2004
 Fifth International Conference on Biology, Prevention and Treatment of GI-Malignancies, Essen, Germany, September 2004
 29th Annual European Society of Medical Oncology Congress, Vienna, Austria, November 2004
 3rd SAGE Meeting, Versailles, France, January 2005
 16th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 2005
 7th World Congress on GI Cancer, Barcelona, Spain, June 2005

First International Conference on Cancer by the National Cancer Institute of Veneto, Monstier di Treviso, Italy, September 2005
 Multi-Model Treatment of GI Cancer, Oslo, Norway, September 2005
 National Cancer Research Institute Symposium, Birmingham, UK, October 2005
 ECCO 13, Federation of European Cancer Society, Paris, France, November 2005
 First Annual World Oncology Congress, New York, NY, November 2005
 FECS8th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2006
 31st ESMO Congress, Istanbul, Turkey, October 2006
 Scientific Symposium -Ulleval University Hospital Cancer Center, Oslo, Norway October 2006
 18th International Congress on Anti-Cancer Treatment, Paris, France, February 2007
 5th International Postgraduate Course: Frontiers in HPB Diseases, Athens, Greece, March 2007
 18th International Congress on Anti-Cancer Treatment, Paris, France, February 2007
 5th International Postgraduate Course: Frontiers n HPB Diseases, Athens, Greece, March 2007
 Clinical Oncology in Croatia – Strategic Planning and Beyond, Zagreb, Croatia, May 2007
 3rd ESO Colorectal Cancer Observatory Session, Barcelona, Spain, June 2007
 9th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2007
 Zhongshan City Peoples Hospital, Zhongshan, China, January 2008
 Shanghai Cancer Hospital and Cancer Institute, Shanghai, China, January 2008
 PUMC – Peking Union Medical College, Peking, China, January 2008
 Sanofi-Aventis GI Summit, Seville, Spain, March 2008
 10th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2008
 IBCC, Paris, France, January 2009
 Expert Session, International Congress on Anti-Cancer Treatment, Paris, France, February 2009
 Presidential Session, International Congress on Anti-Cancer Treatment, Paris, France, February 2009
 Garvan Institute of Medical Research, Pancreatic Cancer Research Group, Australasian Gastro-Intestinal Trials Group (AGITG), Syndey, Australia, June 2009
 11th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2009
 Portuguese Gastrointestinal Cancer Study Group, Portugal, October 2009
 International Congress on Anti-Cancer Treatment, Paris, France, February 2010
 12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2010
 Physician's Education Resource, 12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 2010
 Alberta GI Tumor Group, Alberta, Canada, November 2010

NATIONAL

Annual meeting of the American Society of Clinical Oncology, 1981
 Annual meeting of the American Association of Cancer Research, 1982
 American Association of Cancer Research, 1983
 American Association for Cancer Research, 1984
 Symposium on Pancreatic cancer, University of Nebraska Medical Center, 1984
 Annual Meeting of the American Association of Cancer Research, 1985
 New Developments in Cancer Therapy, 1985
 University of Nebraska Medical Center Continuing Education Program, 1985
 Fifth Annual Congress for Hybridoma Research, 1986
 Course Director / Moderator / Summation Statement, University of NE Medical Center, 1986
 Keystone Conference, 1986

American Association of Cancer Research, 1986
GI Endocrine Tumor Symposium, M. D. Anderson Hospital and Tumor Institute, 1986
National Cancer Institute, 1987
Symposium at the National Institutes of Health, May, 1987
University of Nebraska Medical Center, Emergency Medicine Seminar, 1987
Gastrointestinal Pathology Society's Scientific Session, 1988
Chemoprevention Program's Decision Point Committee, National Institutes of Health, 1988
Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1988
79th Annual Meeting of the American Association for Cancer Research, 1988
24th Annual Meeting of the American Society of Clinical Oncology, 1988
Mayo Clinic, 1988
Food and Drug Administration Conference, 1988
Oncology Update, 1988
Emergency Medicine Review Course, University of Nebraska Medical Center, 1988
Pittsburgh Cancer Institute, 1989
Peter Kiewit Conference Center, 1989
M.D. Anderson Cancer Center Grand Rounds, 1989
Physician Oncology Symposium, Management of Colorectal Cancer, 1989
American Society of Clinical Oncology 26th Annual Meeting, 1990
American Association for Cancer Research 81st Annual Meeting, 1990
Developmental Biologics Symposium, Southwest Oncology Group Fall Meeting, 1990
Design of Antibody Clinical Trials Meeting, Memorial Sloan-Kettering Cancer Center, 1991
40th Annual Scientific Meeting of the Radiation Research Society, March 1992
Oncology Conference, 1992
American Association for Cancer Research, 1992
Mt. Sinai Grand Rounds, 1993
University of Pennsylvania Cancer Center Grand Rounds, 1993
American Society of Clinical Oncology 29th Annual Meeting, 1993
Medical Grand Rounds Presentation at Roswell Park Cancer Institute, 1994
11th Annual Advances in Cancer Treatment Research and 6th Bone Marrow & Stem Cell Transplantation Symposium, Albert Einstein College of Medicine, 1994
National Cancer Institute Organ Systems Program, Invited Chairperson, 1994
5th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, 1994
The 17th Annual Oncology Update, Cedars Medical Center, 1995
Lilly Oncology Global Medical Conference, 1995
American College of Gastroenterology Post Graduate Course, 1995
Iowa Oncology Society Fall Meeting, 1995
Meet the Professor Session, American Society of Clinical Oncology Fall Meeting. 1995
6th Annual Pittsburgh Cancer Conference, 1995
Minnesota Oncology Society, 1996
Medical Oncology Divisional Conference, Mayo Clinic, 1996
Brookhaven National Laboratory Seminar, 1996
Current Topics in Oncology and Radiology, 1996
CALGB 1996 Spring Meeting, GI Committee, 1996
American Gastroenterological Association Fall Postgraduate Course, 1996
Gemzar Scientific Consultants Conference, 1997
National Comprehensive Cancer Network, Second Annual Conference, 1997
Huntsman Cancer Institute Lecture, University of Utah, 1997
Advances in Pancreatic Cancer Treatment Symposium, Ellis Fischel Cancer Center, 1997
U.S. Gemzar Investigators' Meeting, 1997

University of Chicago Lecture, May 1997
ASCO/ESMO Session at the 33rd Annual ASCO Meeting, May 1997
Memorial Sloan-Kettering Cancer Center Grand Rounds, 1997
2nd Annual Rena Schechter Memorial Lecture, Washington University, 1997
University of Pennsylvania Cancer Center Lecture, 1997
New York Hospital-Cornell University Medical Center, 1997
3rd Annual Conference of the National Comprehensive Cancer Center, 1998
Las Vegas Medical Oncologist Meeting, 1998
145th Annual Meeting and Exposition of the American Pharmaceutical Association, 1998
American Association for Clinical Research Annual Meeting, New Orleans, 1998
Eli Lilly and Company 1998 Oncology Global Medical Conference, 1998
AGA Postgraduate Course entitled 1998
Digestive Diseases Week Consensus Conference, 1998
Dana-Farber/Partners CancerCare Grand Rounds, Massachusetts General Hospital, 1998
Hematology/Oncology Conference, University of Alabama at Birmingham, 1998
Grand Rounds, University of Wisconsin Comprehensive Cancer Center, 1998
Hematology/Oncology Lecture, University of Arizona Cancer Center, 1998
Society of Biological Therapy 13th Annual Meeting, 1998
Memorial Sloan-Kettering Cancer Center, 1998
National Comprehensive Cancer Network (NCCN) Fourth Annual Conference, 1999
Gastrointestinal Cancer Conference, Park City, 1999
American Association for Cancer Research Annual Meeting, 1999
Interview on America's Health Network (AHN), 1999
Ohio State University Comprehensive Cancer Center, 1999
Gastrointestinal Cancer Conference, Dana Farber Cancer Institute, 1999
Poster presentation - American Society of Clinical Oncology Annual Meeting, 1999
Fellows Program, Chairperson, American Society of Clinical Oncology Annual Meeting, 1999
7th Annual SPORE Investigators Workshop, 1999
Cancer Center Grand Rounds, University of Indiana, 1999
2nd Annual Conference on Gastrointestinal Cancer, 2000
Oncology Grand Rounds, Lombardi Cancer Center, Georgetown University Medical Center, 2000
36th ASCO Annual Meeting, May 2000
SPORE Retreat, Eppley Institute, University of Nebraska Medical Center, August 2000
Grand Rounds, University of Virginia Health Sciences Center, 2000
NCI Pancreatic Cancer Progress Review Group Roundtable Meeting, 2000
Grand Rounds, Johns Hopkins University Medical Center, 2000
4th Annual Cancer Symposium, Virginia Commonwealth University, MCV Hospitals, 2000
APA/IPA Combined Meeting, 2000
Gastrointestinal Cancer: A Multidisciplinary Approach for the Clinical Conference, 2001
Meet The Experts, AACR 92nd Annual Meeting, 2001
Grand Rounds, Robert H Lurie Comprehensive Cancer Center, 2001
George Washington Medical Center, 2001
3rd Annual Global Oncology Young Investigators' Meeting, 2001
Workshop on Methods in Clinical Cancer Research, 2001
Pancreas Cancer Symposium, Virginia Mason Medical Center, 2001
Rocky Mt Oncology Society Seminar, 2001
University of Colorado Lecture, Denver, 2001
University of Chicago Hematology/Oncology Grand Rounds, 2002
Karmanos Cancer Institute, Grand Rounds, 2002
Gastrointestinal Cancer Research Conference, 2002

Seattle Cancer Care Alliance Symposium, University of Washington, 2003
 GI SPORE Meeting, Arizona Cancer Center, 2003
 Yale Cancer Center, 2003
 American Society for Therapeutic Radiation and Oncology (ASTRO) Annual Meeting, 2003
 Memorial Sloan Kettering Grand Rounds, 2003
 University of Washington Lecture, 2003
 Florida Society of Clinical Oncology, 2004
 AACR Annual Meeting, 2004
 US Lilly Investigators Meeting, 2004
 Sidney Kimmel Comprehensive Cancer Center, 2004
 Update on the Management of Gastrointestinal Malignancies, 2004
 Northwestern University, Medical Grand Rounds, 2004
 The 3rd Annual Symposium on Gastrointestinal Cancers, 2004
 Annual APA Meeting, Northwestern University, 2004
 Career Development Workshop for fellows and Junior Faculty. ASCO Annual meeting, 2005
 NCCN 11th Annual Conference, 2006
 Grand Rounds at University of North Carolina Lineberger Comprehensive Cancer Center, 2006
 National Cancer Institute Imaging Science Workshop, Gaithersburg, MD, 2006
 ASCO GI Symposium, 2007
 NCCN Annual Meeting, 2007
 AACR Annual Meeting, 2007
 International Society of Gastrointestinal Oncology (ISGIO), 2007
 National Cancer Institute - Pancreatic State of the Science Meeting, 2007
 ASCO Annual Meeting, 2008
 CBCE - Recent Advances and New Directions in Cancer Therapy Conference, 2008
 3rd Annual Moffitt Interdisciplinary GI Oncology Conference, 2008
 MD Anderson, GI Cancer Program Research Seminar, 2008
 NCCN 13th Annual Meeting, 2008
 Vanderbilt-Ingram Cancer Center, 2008
 ASCO Annual Meeting – Leadership Orientation Session, 2009
 ASCO Annual GI Symposium, 2009
 NCCN 14th Annual Conference, 2009
 NCCN Best Practices Meeting, 2009
 SAGE GI Cancers Meeting, 2009
 ASCO Annual Meeting – Discussant Presentation, 2010
 NCCN Congress Series: Gastrointestinal Cancers, 2010
 University of Michigan – Laurence H. Baker Visiting Lectureship, 2010

REGIONAL AND OTHER INVITED PRESENTATIONS

1986 Loma Linda University School of Medicine and The American Cancer Society Traveling
 Oncology Consultant Program, CA
 1988 17-1A Club Meeting, La Jolla, CA
 1990 Methodist College, Nursing Symposium
 1991 National Institutes of Health Site Visit at UCLA
 1992 American Cancer Society Workshop on the Pretreatment Diagnostic Management of
 Colorectal Cancer and Follow Up Management of Recurrent Disease, SF, CA
 1996 Association of Northern California Oncologists Meeting, SF and San Diego, CA

- 1997 Colon Cancer Symposium Chair, 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA
- 2000 UCSF/Stanford Gastrointestinal Tumor Board
- 2000 Ask the Experts – Public Forum,” AACR 91st Annual Meeting, SF, CA
- 2000 Redwood Regional Oncology Group Tumor Board, Santa Rosa, CA
- 2000 Recent Advances in the Management of Pancreatic Cancer, UCLA School of Medicine, Beverly Hills, CA
- 2000 Hospital Grand Rounds, Alta Bates Summit Medical Center, Oakland, CA
- 2000 Chemoradiation Summit, Kaweah Delta Cancer Care Program/ St. Agnes Cancer Center/ UCSF – Stanford Health Care, Yosemite, CA
- 2000 Stanford Oncology Research Retreat, Stanford University, Monterey, CA
- 2001 ASCO Annual Meeting, San Francisco, California
- 2001 Institute for Continuing Healthcare Education, San Jose, California
- 2001 Mount Diablo Regional Cancer Center, Concord, California
- 2001 John Muir Medical Center, Walnut Creek, California
- 2001 Redwood Regional Oncology Center, Napa, California
- 2001 Sutter Cancer Center, Sacramento, California
- 2001 Kaiser-Permanente Retreat, Rohnert Park, California
- 2002 Scripps Green Cancer Center Lecture, San Diego, California
- 2002 UC Davis Cancer Center Lecture, Davis, California
- 2003 Scripps Cancer Center Annual Conference of Hematology and Oncology, La Jolla, California
- 2003 Hoag Cancer Center Seminar, Newport Beach, California
- 2003 UCSF/Stanford Gastrointestinal Tumor Board, Silverado, California
- 2003 Medical Oncology Association of Southern California Seminar
- 2003 UC Davis Cancer Center Lecture, Davis, California
- 2003 Santa Rosa Memorial Hospital Lecture, Santa Rosa, California
- 2003 Tumor Board, Enloe Hospital, Chico, California,
- 2003 7th Biannual Conference of Hematology and Oncology, Napa, California
- 2005 Stanford Digestive Disease Center Symposium, Stanford, CA
- 2006 Northern California Tumor Board at Silverado, Napa, California
- 2006 Meeting of Northern California Cancer Registrars’ Association, UCSF
- 2007 Stanford’s 9th Annual Multidisciplinary Management of Cancers, Napa, CA
- 2007 St. Francis Hospital, Medical Grand Rounds, San Francisco, California
- 2007 UCSF, Medical Grand Rounds, San Francisco, California
- 2007 Novartis Clinical Oncology Workshop, Emeryville, California
- 2008 CBCE – Center for Biomedical Continuing Education, San Francisco, California
- 2008 Stanford - 10th Annual Multidisciplinary Management of Cancers, Napa, California
- 2009 UCSF - Molecular & Cellular Biology of Cancer, January, San Francisco, California
- 2009 UCSF - Molecular & Cellular Biology of Cancer, March, San Francisco, California
- 2009 UCSF – Clinical Research Retreat - Fellows “Career Development”, SF, CA
- 2009 UCSF - Division of Hematology / Oncology Research Retreat - SOTA Lecture: Therapy Development in Pancreatic Cancer, San Francisco, California
- 2009 Stanford -11th Annual Multidisciplinary Management of Cancers, Napa, California
- 2009 UCSF – Controllers Office – Cancer Research, SF, California
- 2009 University of San Francisco – Women in Science Club, SF, California

GOVERNMENT and OTHER PROFESSIONAL SERVICE:

International Government

2008-present	Strategic Advisory Committee, European Organization for Research and Treatment of Cancer, (EORTC) Member
2008-2010	Alberta Canada Cancer Board – IACOR, Member
2009	European Commission's 7 th Framework Programme for Research, Consensus Group, Member
2010-2011	Canadian Institutes of Health Research (CIHR), Expert Review Committee, Member

Cancer and Leukemia Group B

1996-present	GI Core Committee, Member
1996	Pancreatic Subcommittee, Chairperson
1998	Conflict of Interest Committee, Member
2001-present	GI Intergroup Pancreas Cancer Task Force, Member

Food and Drug Administration

2007-present	Oncologic Drugs Advisory Committee(ODAC), Member
--------------	--

NATIONAL CANCER INSTITUTE (NCI) /NATIONAL INSTITUTES OF HEALTH (NIH)

1992	Consensus Development Conference on Diagnosis and Treatment of Early Melanoma, Panel, Member
1995-1999	NCI/NIH Cancer Centers & Research Programs Review Committee – Subcommittee A, Member
1998-1999	NIH Committee, Clinical Oncology Special Section, Founding Chair
1999-2004	Board of Scientific Counselors, Subcommittee A, Group One, Member
2004-2006	Member; Chair
2001	Progress Review Group for Pancreatic Cancer, Co-Chair
2001-present	GI Intergroup Pancreas Cancer Task Force, Member
2008-present	State of the Science Meeting for Pancreatic Cancer, Steering Committee Member
2010-present	Pancreas Task Force Tissue Acquisition Working Group, Co-Chair
2010	Stakeholders Workshop, Maryland, Virginia

NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN)

1995-1997	Executive Board, Member
1997-2001	Vice-Chair
1995-2001	Colorectal Cancer Guidelines Committee, Member
1996-present	Pancreatic Cancer Guidelines Committee, Chair
1997-present	CME Advisory Committee, Member
2009-present	Oncology Research Program (ORP), Contract Working Group, Member
2009-present	Scientific Review Committee, Pancreatic Cancer Research Grants, Chair

Scientific Advisory Boards

Not For Profit:

1999-present Pancreatic Cancer Action Network (PanCAN), Member
1999-present Lustgarten Foundation, Member
2004-present V Foundation, Member
2007-present Wayne D. Kuni and Joan E. Kuni Foundation, Member
2009-present Columbus Cancer Research Foundation
2010-present Oatmeal Science, Member

For Profit:

2004-2008
2003-2008
1998-2007
2002-2005
2004-present
2004-2008
2004-2009
2007-2010
2008-present
2008-2009
2008-2009
2008-2009
2008-2009
2008-2009
2008-2009
2008-2009
2009
2009-present
2010-present
2010-2012

(b) (4)

Academic Advisory Committees

1997-2007 Northwestern University, Robert H. Lurie Cancer Center, Member
1998-2006 University of Colorado Cancer Center, Chair
2000-2002 Walther Cancer Institute Scientific Clinical Review, Member
2000-present Pancreas SPORE External Advisory Board, M.D. Anderson, Member
2001-2008 Oregon Health Science Hospital Cancer Institute, Member
2001-present Arizona Cancer Center, GI SPORE External Advisory Board, Member
2009-2012 University of Illinois Cancer Center, External Advisory Board, Member

REGIONAL SERVICE

1992 Veteran's Administration Regional Oncology Advisory Committee
1986-94 American Cancer Society, Professional Education Committee, Vice Chairperson
2000-present MT Zion Health Fund, Board of Directors, Member
2001-present Association of Northern California Oncologists, UCSF representative to the Board of Directors
2005 UCSF Osher Lifelong Learning Institute, Course Organizer, Fall

2007-2010	Print Interviews: Bloomberg News, UCSF Catalyst Newsletter, NY City News Service, Fortune Magazine, Healthcare Journal of Northern California, Hem/Onc Today – AMA, Los Angeles Times, San Jose Mercury News, New York Times, USF Magazine, Wall Street Journal
2007	Film, Documentary: PBS World of Cancer, 2007
2008	Radio Interview: KGO-TV
2010-2013	University of San Francisco, Board of Trustees, Member

UNIVERSITY AND PUBLIC SERVICE

UNIVERSITY SERVICE

SYSTEMWIDE

2000-2006 University of California Cancer Centers Alliance, Member

UCSF CAMPUS-WIDE

2000-2002	Hellman Award Committee, Member
2000-present	Clinical Research Executive Committee, Member
2001-2003	Ambulatory Services Committee, Member
2001-2002	Mount Zion Subcommittee of the Chancellor's Advisory Committee on the 2002 LRDP Amendment, Member
2002-2006	Medical Staff Committee, Member
2008–2009	Research Advisory Board (RAB) and Subcommittee, Member
2008–present	Academic Information Systems Board (AISB), Member
2008–present	Resource Allocation Program (RAP), Cancer Review Group, Co-Chair
2008–present	Global Health Sciences Graduate Group, Member
2009-2010	Vice-Chancellor for Research, Search Committee, Member

SCHOOL OF MEDICINE

2000-present	Clinical Practice Organization, Member
2000-2004	Clinical Practice Organization, Finance Subcommittee, Member
2000-present	Fundraising Advisory Council, Member
2000-2004	School of Medicine Clinical Research Executive Committee, Member
2000-present	Department of Orthopedics Chairperson, Search Committee, Member
2000-present	Dean's Strategic Planning Committee, Member
2001-2008	Division of GYN Oncology Chief, Search Committee, Member
2001	Department of Otolaryngology, Chairperson Search Committee, Member
2002	Physician Scientist Program Clinic-based Task Force (PSPC), Member
2003	School of Medicine Associate Chair for Clinical Research, Search Committee, Member
2003-2007	Steering Committee for Physician Scientist Program – Clinic Based, Member
2005	Department of Radiation Oncology Chairperson Search Committee, Chairperson
2007-2008	Research Data Systems Steering Committee, Member
2008–2009	CTSI CRC Program Director, Search Committee, Chair
2009–present	CTSI Biospecimen Strategic Task Force, Member

DEPARTMENTAL SERVICE

2000-2007 Chief, Hematology and Oncology
2007-Present Division of Heme/Onc, Fellowship Steering Committee, Member

UCSF Helen Diller Family Comprehensive Cancer Center:

2000-present Executive Committee, Member
2000-present Strategic Planning Committee, Member
2000-2003 Clinical Activities Executive Committee, Chair
2000-present Program Planning Committee, Member
2000-present Cancer Center CIRP Award Committee, Chair
2001-2007 ACS Institutional Research Grant Review Committee, Member
2001 Assistant Director of Education and Outreach, Search Committee, Member
2001-2002 Cancer Center Funds Flow Committee, Co-chair
2001-2006 Ethel and Jane Sokolow Memorial Cancer Endowment Lectureship Committee, Member
2002-2008 Cancer Center Operations Group, Chair
2002-2008 Cancer Center Governing Board, Member
2003-present Cancer Center Directors Group, Member
2003 Associate Director-Administration Search Committee, Member
2003-2008 Cancer Center Minority Task Force
2006-present Mission Bay Steering Committee, Member
2006-present Mission Bay Executive Decisions Group, Member
2006-2009 Cancer Center Informatics Working Group, Chair
2006-2008 Hematologic Malignancies Service Line Operations Board, Member
2006-2008 Hematologic Malignancies Governing Board, Member
2007-present Cancer Center Space Planning Group, Co-Chair

UNIVERSITY OF NEBRASKA COMMITTEES:

College of Medicine Committees:

Alpha Omega Alpha, Alumni and Faculty Committee - Member, 1987-1988
Alpha Omega Alpha Committee for Visiting Professorship and Scholarly Pursuits, Member 1989-92; Chairperson, 1992-1999
Chancellor's Leadership Council, 1997, Member
College of Medicine Strategic Plan - Cancer Committee, 1995-1999, Chairperson

(b) (6)



UNMC Clinical Advisory Committee of the Clinical Research Center, 1996-2000, Member
 Radiation Oncology Chair Search Committee, 1997-98, Chairperson
 Liaison Committee on Medical Education Self Study Task Force, 1997-1999, Member

Hospital Committees:

Oncology Service Line Committee, Member, 1995-1999
 National Comprehensive Cancer Network, UNMC Steering Committee Chairperson, 1995-1999
 Pharmacy & Therapeutics Committee, 1984-1985, Member; 1985-1988, Chairperson
 Quality Assurance Committee, 1985-1988, Member
 Clinical Cancer Center Administrative Committee, 1991-1999, Member
 Distinction Through Quality, University East Committee, 1992-95, Member
 UNMC Home Health Care Selection Committee, 1993, Member
 Research Committee for UNMC Lied Transplant Center, 1994-1999, Member

Departmental Committees:

Graduate Education Committee, 1984-1995, Member
 Internal Medicine Clinical Section Team, 1994-1997, Member
 Internal Medicine Gender Equity Committee, 1994-1996, Chairperson

OMAHA VETERAN'S ADMINISTRATION COMMITTEES:

Veteran's Administration Subcommittee on Animal Use, 1984-1985, Member
 Veteran's Administration Committee on Research & Development, 1986-1989, Member
 Veteran's Administration Blood Transfusion Committee, 1987-1999, Chairperson

RESEARCH AWARDS AND GRANTS

CURRENT

- | | |
|---|---|
| 1. R21 CA137429 SNAP (Liu)
National Cancer Institute/NIH
Selection of internalizing human antibodies targeting pancreatic
tumor cells in situ by laser capture microdissection | 02/01/09 – 01/31/2011
\$132,000 direct/yr 1
\$242,000 direct /Yrs 1-2 |
| 2. P30 CA82103 (McCormick)
Cancer Center Support Grant
The Cancer Center Support Grant provides support for administration and infrastructure for the
UCSF Comprehensive Cancer Center. Dr. Tempero is Deputy Director and Program Leader of
the Pancreas Cancer Program. | 08/05/99 – 05 /31/12
NIH/NCI\$4,924,703 direct/current yr |
| 3. (b) (4) | 07/20/07 – 05-31/10
\$ (b) (4)/Yr 1 |

Margaret A. Tempero, M.D.

\$ (b) (6) Yrs 1-3

PAST

1. U54 CA90788

09/26/01-12/31/08

NCI

\$5,527,794 (direct)

Mechanism-Based Evaluations of ErbB-Targeted Agents

Interdisciplinary Research Teams for Molecular Target Assessment

The major goal of this project is to develop novel ErbB-targeted probes and assays to provide clinically applicable assessments of ErbB receptor function in the setting of ErbB-targeted therapies.

Role: PI, Administrative Core Director

2. P30 CA 82103-04 (McCormick)

08/01/02-05/31/07

NCI

\$4,732,522

Cancer Center Support Grant

This grant provides support for Cancer Center infrastructure and Program leadership. Dr. Tempero is the Deputy Director for this grant.

3.

(b) (4)

10/22/01-07/14/06

(b) (4)

4. 3P50-CA72712-03S2

01/01/00-01/31/02

University of Nebraska, HIH/NCI

\$207,392

Principal Investigator of Project 1 – Part 1, Optimizing Radioimmunotherapy for Pancreatic Cancer;

Major Goals: These trials explored biodistribution and pharmacokinetics of CC49 fusion and PRIT and the possibility of multi-dose treatment strategies. Role: PI Overlap: None

5.

(b) (4)

03/01/99-2/28/01

(b) (4)

6. 1 P50 CA72712

9/01/97-8/31/00

NIH/NCI

\$7,217,565 (total award)

Principal Investigator “Special Program of Research Excellence in Gastrointestinal Cancer”

7.

(b) (4)

11/16/98 – 11/30/99

(b) (4)

8.

(b) (4)

11/19/98 – 11/30/99

(b) (4)

9.

(b) (4)

2/1/98 – 1/31/00

(b) (4)

10.

(b) (4)

1/1/97 - 12/31/99

(b) (4)

11. (b) (4) 7/10/97 – 7/10/00

(b) (4)

12. (b) (4) 7/1/96 – 6/30/99

(b) (4)

13. (b) (4) 6/18/98 – 9/30/99

14. 1 U01CCA58272-01 9/30/93 - 9/29/00
NCI/NIH \$405,423
Principal Investigator - "Defining Toxicity and Benefit for Radioimmunotherapy"

PEER REVIEWED PUBLICATIONS:

1. Tempero MA and Smith PW: Disseminated mycobacterial kansasii presenting with skin lesions in a patient with chronic lymphocytic leukemia. Medical & Pediatric Oncology 9:283-288, 1981. PMID: 7242466
2. Tempero MA, Foley JF and Kessinger A: VP-16-213 therapy after failure with combination chemotherapy for small cell carcinoma of the lung. Clinical Cancer Trials 4:155-157, 1981. PMID: 6265110
3. Tempero MA, Petersen R, Zetterman RK and Lemon HM: The liver scan and biochemical liver tests in the detection of metastatic disease. JAMA 248:1329-1332, 1982. PMID: 7109154
4. Tempero MA and Kessinger A: Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma. J Surg Oncology 21:159-161, 1982. PMID: 6813600
5. Tempero MA, Lynch HT, Jacobs M, Graham C and Blotcky A: Selenium levels in hereditary non-polypoid colorectal cancer. Biol Trace Elements Res 6:51- 55, 1984.
6. Tempero MA, West W, Zetterman RK: The effect of increasing amounts of dietary cellulose fiber in the presence of dietary cholesterol in experimental colon cancer. J of Nutrition, Growth & Cancer 1: 197-206, 1984.
7. Tempero MA, Davis RB, Reed E, and Edney J.: Thrombocytopenia and Laboratory Evidence of Disseminated Intravascular Coagulation after Shunts for Ascites in Malignant Disease. Cancer 55:2718-2721, 1985. PMID:3995480
8. Berg AR, Linder J, Anderson RA, Tempero MA, Edney JA, Armitage JO: The Undifferentiated Malignant Neoplasm: Identification of Lymphoma Arising in Skeletal

- Muscle by Immunohistochemistry. JAMA 254:2625-2626, 1985. PMID: 2414476
9. Thompson JS, Tempero MA, Haun JL and Vanderhoof JA: The importance of luminal factors in neomucosal growth. J Surg Res 40:126-132, 1986. PMID: 3945070
 10. Tempero MA, Van de Walle C and Anderson J: The Value of Hepatic Ultrasound and Biochemical Liver Tests in Screening for Liver Metastases. J Clin Oncol 4:1074-1078, 1986. PMID: 3522817
 11. Tempero MA, Deschner EE and Zedeck MS. The Effect of Selenium on Cell Proliferation in Liver and Colon. Biol Trace Elements Res 10:145-152, 1986.
 12. Lyn D, Sears H, Dimitris I, Lubeck M, Douillard J, Sindelar W, Tempero MA, Meelsted H, Maher M, and Koprowski H. Anti-idiotypic Antibodies to Monoclonal Antibody CO17-1A. Hybridoma 5:Supl 1:S51-S58, 1986. PMID: 3744378
 13. Tempero MA, Pour PM, Uchida E, Herlyn D, and Steplewski Z: Monoclonal Antibody CO17-1A and Leukopheresis in Immunotherapy of Pancreatic Cancer. Hybridoma, 5:Supl 1: S133-S138. 1986. PMID: 3744378
 14. Petrie H, Tempero MA, Klassen L and Kay D: In Vitro Regulation of Human Lymphocytic Proliferation by Selenium. Biol Trace Element Res, 11:129-146, 1986.
 15. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, and Pour PM. Comparative studies on expression of CA 19-9 and Du-Pan-2 in Pancreatic Cancer Tissue. International J Pancreat 2:349-360, 1987. PMID: 3320227
 16. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, and Pour PM: The Relationship of CA 19-9 and Lewis Antigens in Pancreatic Cancer. Cancer Res 47:5501-5503, 1987. PMID: 3308077
 17. Uchida E, Tempero MA, Burnett DA, Steplewski Z, and Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detection and Prevention Suppl 1:145-148, 1987. PMID: 3319143
 18. Tempero MA, Zetterman RK: The Effects of Sodium Cholate on Experimental Carcinogenesis and Cell Proliferation in an Isolated Colonic Segment. J. Surg. Onc. 36:253-258, 1987. PMID: 3695530
 19. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RG and Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of patients with pancreatic cancer. Cancer Research 2:349-360, 1987. PMID: 3162196
 20. Ness MJ, Pour PM, Tempero MA, and Linder J. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Modern Pathology 1:279-283, 1988. PMID: 2467286
 21. Pour PM, Tempero MA, Takasaki H, Uchida E, Takiyama Y, Burnett DA and Steplewski Z. Expression of blood group-related antigens, ABH, Lewis a, Lewis b, Lewis x and Lewis y and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Research 48:5422-5426, 1988. PMID: 3166398
 22. Takasaki H, Tempero MA, Uchida E, Buchler M, Ness MJ, Burnett DA, Metzgar RS,

- Colcher D, Schlom J and Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. *Int J Cancer* 42:681-686, 1988. PMID: 3053465
23. Tempero MA, Knott K, and Zetterman RA. The Relationship of Dietary Cholesterol and Cellulose in the Prevention of Colon Cancer. *Journal of Cancer Detection and Prevention* 13:41-54, 1988. PMID: 3224345
24. Tempero M, Takasaki H, Uchida E, Takiyama Y, Colcher D, Metzgar RS and Pour PM. Co-expression of CA 19-9, CA 125 and TAG-72 in pancreatic carcinoma. *Amer J Surg Path* 13(Suppl 1):89-95, 1989. PMID: 2699170
25. Tempero MA, Nishioka K, Knott K and Zetterman RK. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. *Cancer Research* 49:5793-97, 1989. PMID: 2507137
26. Wettendorf M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-*Proc Natl Acad Sci* 86:3787-91, 1989. PMID: 2786203
27. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, and Kay HD: Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: Biologic and clinical effects. *J Clin Oncol* 12:2019-2026, 1990. PMID: 2121912
28. Egami H, Tsutomu T, Tempero M, Kay D, Pour PM. Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. *Amer J Pathology* 138:557-561, 1991. PMID: 2000935
29. Tempero MA. Progress in chemoprevention of gastrointestinal cancers. *Curr Opinion in Oncology* 3:719-726, 1991. PMID: 1834193
30. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, and Pour P. Immunotherapy with monoclonal antibody (MAb) in pancreatic adenocarcinoma. *Int J Pancreatol* 9:125-134, 1991. PMID: 1744438
31. Haga Y, Kay HD, Tempero MA, Zetterman R. Characterization of bilirubin transport system by human peripheral blood mononuclear cells. Evidence of preferential uptake of bilirubin by monocytes. *J Leukocyte Biology* 51:2-6, 1992. PMID: 1740642
32. Haga Y, Sivinski CL, Kay HD, McDonald TL, Khazaeli MB, Blottier HM, Steplewski Z, Harvey E, and Tempero MA. Biologic responses to multiple high doses of murine monoclonal antibody (17-1A) in pancreatic cancer patients. *Antibody Immunonconj Pharm* 5:179-190, 1992.
33. Hirota M, Pour PM, Tempero MA and Chaney WG: Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. *Carcinogenesis* 13:1829-1833, 1992. PMID: 1385001
34. Haga Y, Kay HD, Tempero MA, and Zetterman R. Flow cytometric measurement of intracellular bilirubin in human peripheral blood mononuclear cells exposed to unconjugated bilirubin. *Clin Biochem* 25:277-283, 1992. PMID: 1381998
35. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG.

- Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-1A fragments. *Tumor Biol* 13:195-206, 1992. PMID: 1411138
36. Tempero M, Colcher D, Dalrymple G, Harrison K, Holdeman K, Joshi S, Quadri S, Linder J, Augustine S, Reed E, and Leichner P. Cancer therapy using radioimmunoconjugates: Implications for breast cancer. *Ann NY Acad Sci*, 698:406-417, 1993. PMID: 7906252
 37. Haga Y, Sivinski CL, Woo D, and Tempero MA. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A: Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. *Int J Pancreatol*, 15:43-50, 1994. PMID: 8195641
 38. Tempero M, Berg A, Block M, Hutchins M, Langdon R, Moravec D, Tweedy C, and Anderson J. A phase II trial of protracted therapy with 5-Fluorouracil and daily oral leucovorin in metastatic colorectal cancer. *J Infusional Chemotherapy* 4:112-115, 1994.
 39. Kornbot B, Kobayashi RH, Singer A, Tempero M, and Heiner D. Hypersensitivity to therapeutic murine monoclonal antibodies. *Nebr Med Journal* 79:393-398, 1994. PMID: 7870212
 40. Tempero MA, Haga Y, Sivinski C, Birt D, Klassen L, and Thiele G. Immunologic effects of levamisole in mice and men: Evidence for augmented antibody response without modulation of cellular cytotoxicity. *Journal of Immunotherapy* 17:47-57, 1995. PMID: 7728305
 41. Kessinger A, Bishop M, Anderson J, Armitage J, Bierman P, Reed E, Tarantolo S, Tempero M, Vose J: A comparison of subcutaneous and intravenous administration of rhGM-CSF for peripheral blood stem cell mobilization. *J Hematotherapy* 4:81-84, 1995. PMID: 7543352
 42. McCashland RM, Bashir R, Tempero MA and Quigley EMM. Dysphagia and diffuse esophageal spasm as the presenting manifestation of a glucagonoma-neuropathy syndrome. *Diseases of the Esophagus*, 8:74-77, 1995.
 43. Sivinski CL, Lindner DJ, Borden EC, and Tempero MA: Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells *in vitro* by alpha and gamma interferons. *J Immunotherapy* 18:156-165, 1995. PMID: 8770771
 44. Haga Y, Tempero MA, Rowen K and Zetterman R: Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. *Biochimica et Biophysica Acta* 1317:65-70, 1996. PMID: 8876628
 45. Haga, Y, Tempero, MA, Rowen, K, Zetterman, R: Unconjugated bilirubin inhibits in vitro major histocompatibility complex-unrestricted cytotoxicity of human lymphocytes. *Biochimica et Biophysica Acta* 1316:29-34, 1996. PMID: 8634340
 46. Haga Y, Tempero MA, Kay D, and Zetterman R: Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutinin-induced proliferation and interleukin-2 production of human lymphocytes. *Digestive Diseases and Science* 41:1468-1474, 1996. PMID: 8689926
 47. Engstrom P, Benson AB, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, and Tempero M: NCCN colorectal cancer practice guidelines. *Oncology* 10:140-175, 1996. PMID: 8953601

48. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, and Chiou RK: Radiolabeled iododeoxyuridine: Safety evaluation. *J Nucl Med* 37:13-16, 1996. PMID: 8676196
49. Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, and Colcher D: Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72. *J Clin Immunol* 17:96-106, 1997. PMID: 9049790
50. Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wisecarver J, and Colcher D: High dose therapy with ¹³¹I labeled monoclonal antibody CC49: A phase I trial. *J Clin Oncol*, 15:1518-1528, 1997. PMID: 9193348
51. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver JA, and Tempero MA: Patient-specific dosimetry of Indium-111/Yttrium-90-labeled monoclonal antibody CC49. *J Nucl Med* 38:512-516, 1997. PMID: 9098192
52. Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, and Tempero MA: Arterial infusion chemotherapy in the treatment of isolated hepatic colorectal metastases. *Semin Interventional Radiology* 14:241-53, 1997.
53. Brand R, Capadano M, and Tempero M: A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with non-hematologic malignancies. *Invest New Drugs* 15:331-341, 1997. PMID: 9547676
54. Habbe TG, McCowan TC, Goertzen TC, LeVeen RF, Culp WC, and Tempero MA: Complications and technical limitation of hepatic arterial infusion catheter placement for chemotherapy. *Journal of Vascular and Interventional Radiology* 9:233-239, 1998. PMID: 9540905
55. Tempero M: Pancreatic Cancer. *Clin Perspectives in Gastroenterology* 1:96-100, 1998.
56. Vose JM, Colcher D, Gobar L, Bierman PJ, Augstine S, Tempero M, Leichner P, Lynch JC, Goldenber D, and Armitage JO: Phase I/II trial of multiple dose ¹³¹Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. *Leukemia and Lymphoma*, 38: 91-101, 2000. PMID: 10811451
57. Gwilt PR, Tempero M, Kremer A, Connolly M, and Ding C: Pharmacokinetics of levamisole in patients treated with 5-Fluorouracil. *Cancer Chemother Pharmacol.*, 45(3):247-51, 2000. PMID: 10663643
58. Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryant K, Fisher DR, Colcher D, Horak ID, and Weiner LM: Phase II trial of yttrium-90-DOTA-BIOTIN targeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. *Clinical Cancer Research* 6:406-412, 2000. PMID: 10690517
59. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, and Colcher D: High dose therapy with ⁹⁰Yttrium labeled monoclonal antibody CC49: A phase I trial. *Clin Cancer Res.* 6:3095-3102, 2000. PMID: 10955789

60. Vose, J, Colcher, D, Gobar, L, Bierman, PJ, Augustine, S, Tempero, M, Leichner, P, Lynch, JC, Goldenberg, D, Armitae, JO: Phase I/II trial of multiple dose ¹³¹I-iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma, Leukemia and Lymphoma. 38: 91-101, 2000. PMID: 10811451
61. Goel, A, Augustine, S, Baranowska-Kortylewicz, J, Colcher, D, Booth, B, Pavlinkova, G, Tempero, M, and Batra, S. Single -dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using ¹³¹I-labeled multivalent CC49 single chain Fvs. Clin Cancer Res. 7:175-84, 2001. PMID: 11205906
62. Rutar, FJ, Augustine, SC, Colcher, D, Siegel, JA, Jacobson, DA, Tempero, MA, Dukat, VJ, Hohenstein, MA, Gobar, LS, Vose, JM. Outpatient Treatment with ¹³¹I-anti-B1 antibody: radiation exposure to family members. J. Nucl Med. 42:907-915, 2001. PMID: 11390555
63. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol, May 1;19(9):2404-12. 2001. PMID: 11331319
64. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. A white paper: the product of a pancreas cancer think tank. Cancer Res, Jun 15;61(12):4923-32, 2001.
65. Augustine, S, Norenberg, J, Colcher, D, Vose, J, Gobar, L, Dukat, V, Hohenstein, M, Rutar, F, Jacobson, D, Tempero, M. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J of Amer Pharma Association 42:93-100, 2002. PMID: 11833524
66. Kurizaki, T, Okazaki, S, Sanderson, S, Colcher, D, Enke, C, Tempero, M, Baranowska-Kortylewicz, J. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J of Nuc Med, 43 (7): 957-67, 2002. PMID: 12097469
67. Sudan, D, DeRoover, A, Chinnakotla, S, Fox, I, Shaw, B Jr., McCashland, T, Sorrell, M, Tempero, M, Langnas, A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2(8): 774-9, September 2002. PMID: 12243499
68. Tempero, M, Plunkett, W, Ruiz van Haperen, V, Hainsworth, J, Hochster, H, Lenzi, R, Abbruzzese, J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. September 15; 21 (18); 3402-8, 2003. PMID: 12885837
69. Blackstock, A., Tepper, J, Niedwiecki, D, Hollis, D, Mayer, R, Tempero, MA. Cancer and Leukemia Group B (CALGB) 89805: Phase II Chemoradiation Trial Using Gemcitabine in Patients with Locoregional Adenocarcinoma of the Pancreas. IJGC, vol 34/2, pp 109-118, 2004. PMID: 15361643
70. Ko, A.H., Hwang, J., Venook, A.P., Abbruzzese, J., Bergsland, E.K, Tempero, M.A. Serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Brit J Cancer, 93(2):195-9, July 2005. PMID: 15999098
71. Ko, A.H., Dito, E., Schillinger, B., Venook, A.P., Bergsland, E.K., Tempero, M.A. Phase II

Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. *J Clin Oncol.* 24(3): 379-85, January 2006. PMID: 16344320

72. Hruban, R.H., Rustgi, A.K., Brentnall, T.A., Tempero, M.A., Wright, C.V., and Tuveson, D.A. Pancreatic Cancer in Mice and Man: The Penn Workshop 2004. *Cancer Res* 66(1): 14-7, January, 2006.
73. Jhawer, M, Rosen, L, Dancey, J, Hochster, H, Hamburg, S, Tempero, M.A., Clendeninn, N, Mani, S. Phase II Trial of Nilotrexed Dihydrochloride [Thymitaq, AG 337] in Patients with Advanced Hepatocellular Carcinoma. *Invest New Drugs.* 25(1):85-94, February, 2007. PMID: 16957834
74. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2007 Jul 1;68(3):809-16. Epub 2007 Mar 23
75. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. *Cancer Invest.* 2008 Feb;26 (1):47-52. PMID: 18181045
76. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? *Invest New Drugs.* 2008 Oct;26(5):463-71. Epub 2008 Apr 1.
77. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, and Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving fixed-dose rate gemcitabine. *Pancreas.* 2008 Oct; 37(3):269-74.
78. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. *Gastroenterology.* 2009 Jan;136(1):43-5. Epub 2008 Nov 28.
79. Kulke MH, Tempero MA. Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsh SM, Goldberg RM, Mayer MJ. Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination with Cisplatin, Docetaxel, or Irinotecan in Patients with Metastatic Pancreatic Cancer. *J Clin Oncol.* 2009 Nov 20;27(33):5487-91.
80. Philip, PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol NJ, Emens, L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus Report of NCI Clinical Trials Planning Meeting on Pancreas Cancer Treatment. *J Clin Oncol.* 2009 Nov 20;27(33):5660-9. Epub 2009 Oct 26.
81. Ko AH, Venook AP, Bergsland EK, Kelley RJ, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. *Cancer Chemother Pharmacol* 2010 Feb 4.
82. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Omori A, Cooc J, Weinkle

J, Kim GE, Jakkula L, Feiler HS, Ko HA Dannenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy. *Nature Medicine*, submitted: March 2010.

83. Tempero, M A, Arnoletti, J P, Behrman, S, et al. (2010). Pancreatic adenocarcinoma. *Journal of the National Comprehensive Cancer Network*. J Natl Compr Canc Netw. 2010 Oct;8(9):972-1017.
84. The International Cancer Genome Consortium (ICGC). International network of cancer genome projects. *Nature* 464, 993-998. 2010 Apr;8 doi:10.1038.
85. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. *Cancer Chemother Pharmacol*. 2010 Nov;66(6):1051-7. Epub 2010 Feb 4.

Review Articles

1. Tempero MA: Bile Acids, Ornithine Decarboxylase and Cell Proliferation in Colon Cancer: A Review. *Survey Dig Dis* 4:49-56, 1986.
2. Tempero MA: Advances in the medical management of advanced gastrointestinal cancers. *Current Opinions in Oncology* 2:747-753, 1990.
3. Tempero, MA. Pitfalls in antibody imaging in colorectal cancer. *Cancer* 71, 4248, 1993.
4. Tempero M. The emerging uses of radioimmunoconjugates in the management of gastrointestinal cancers. *Hem/Onc Ann*, 2:213-224, 1994.
5. Tempero M and Anderson J. Editorial: Progress in colon cancer - Do molecular markers matter? *N Engl J Med* 311:267-268, 1994.
6. Tan-Shalaby J and Tempero M: Malignancies after liver transplantation: A comparative review. *Semin Liver Dis* 15:156-164, 1995.
7. Tempero MA, Brand R, Holdeman K, and Matamoros: A new imaging technique in colorectal cancer. *Semin Oncol* 22:448-471, 1995.
8. Harrison KA and Tempero MA: Diagnostic use of radiolabeled antibodies for cancer. *Oncology* 9:625-63, 1995.
9. Tempero, MA: Walking a difficult path is easier with a friend: Thoughts from a practicing oncologist. *Ann New York Academy of Sciences* 809:237-242, 1997.
10. Tempero MA: Review: Recent progress in radioimmunotherapy cancer. Meridith RF and LoBuglio AF (authors). *Oncology* 11:987, 1997.
11. Tempero MA, Abbruzzese J, Benson AB, Cameron JL, Casper ES, Hoffman J, Lawrence T,

Martin T, McGinn C, and Willett C: NCCN practice guidelines for pancreatic cancer. NCCN Proceedings, Oncology 11:41-56, 1997.

12. Brand RE and Tempero MA: Pancreatic cancer. Curr Opin Oncol 10:362-366, 1998.

13. Tempero M and Brand R: Letter to the Editor, Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 82:1800-01, 1998.

14. Tempero M: Chemotherapy for Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, July/August 1999.

15. DiMagno EP, Reber HA, and Tempero MA: AGA Technical Review and Medical Position Statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117:1463-1484, 1999.

16. Tempero M: Commentary: Irinotecan increased survival in patients with advanced colorectal cancer. Evidence-based Oncology, Preview Issue, 2000.

17. Ko, A, Tempero, MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep, 12: 39-45, 2002.

18. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. JNCCN 2005 Sep;3(5):627-36. Review PMID: 161944

19. Ko, A.H., Tempero, M.A. Systemic therapy for pancreatic cancer. Semin Radiat Oncol 15(4):245-53, October 2005.

20. Tempero MA, Behrman S, Ben-Josef E, Benson AB 3rd, Cameron JL, Casper ES, HoffmanJP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW 2nd, Melvin WS, Muscarella P 2nd, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA; National Comprehensive Cancer Network. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. JNCCN. 2005 Sep;3(5):598-626. No abstract available. PMID: 16194453

22. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov;5(10):998-1033. Review. PMID: 18053426

23. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007;3(1):1-33. PMID: 17655039

24. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcborg J. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. *Ann Oncol.* 2007 Jun;18 Suppl 7:vii1-vii10. PMID: 17600091
25. E. Van Cutsem, M. Dicato, K. Haustermans, N. Arber, J.-F Bosset, D. Cunningham, A. De Gramont, E. Diaz-Rubio, M. Ducreux, R. Goldberg, R. Glynne-Jones, D. Haller, Y.-K. Kang, D. Kerr, R. Labianca, B. D. Minsky, M. Moore, B. Nordlinger, P. Rougier, W. Scheithauer, H.-J. Schmoll, A. Sobrero, J. Tabernero, M. Tempero, C. Van de Velde & J. Zalcborg. The diagnosis and management of rectal cancer, expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 *Annals of Oncology* 19 (Supplement 6): vi1–vi8, 2008
26. Ko AH, Tempero MA Personalized medicine for pancreatic cancer: a step in the right direction. *Gastroenterology*. 2009 Jan;136(1):43-5. Epub 2008 Nov 28. PMID: 19041
27. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. Consensus Report of the National Cancer Institute clinical Trials Planning Meeting on Pancreas Cancer Treatment. *J Clin Oncol.* 2009 Nov 20;27(33):5660-9. Epub 2009 Oct 26.
28. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll H-J, Sobrero A, Van Cutsem E. Pancreatic Cancer Treatment and Research: An International Expert Panel Discussion. *Annals of Oncology* 2011; doi: 10.1093/annonc/mdq545

BOOKS

Ratain, M, Tempero, M, Skosey, C. **Outline of Oncology Therapeutics**. W.B. Saunders Company, 2001.

Dollinger, M, Rosenbaum, E, Tempero, M. **Everyone's Guide to Cancer Therapy**, Somerville House Books Limited, 2001.

Book Chapters, Monographs

1. Tempero MA, Uchida E, Takasaki H, Kay HD, and Pour PM. Biologic studies in pancreatic cancer. In: *New Trends in Gastroenterology* Sugahara K, Ed; pp 135-151, 1987.
2. Armitage JO, Gingrich RD, Foley JF, Kessinger MA, Klassen LW, Kumar PP, Tempero MA, and Vaughan WP. Which Patient with Lymphoma Can Be Salvaged with High-Dose Cytoreduction and Autologous Marrow Rescue? In: *Autologous Bone Marrow Transplantation: Proc 1st International Symposium* Dicke KA, Spitzer G and Zander AK, Eds; pp 57-62, 1985.

3. Pour PM and Tempero MA. Blood Group Antigenicity of Gastrointestinal Cancers. In: New Tumor Markers and their Monoclonal Antibodies (Klapdor R, Ed); pp 315-318, 1987.
4. Tempero MA: Genetics of Colon Cancer at the Infrahuman Level. In: Genetic Epidemiology of Cancer (Lynch H and Hirayama T, Eds.), CRC Press, Inc.; 1989.
5. Pour PM, Egami H, Chaney WG, Takiyama Y, Tempero MA, Schlom J, and Colcher D. Comparative studies on antigen expression in human and experimental pancreatic cancer. In: Recent Results in Tumor Diagnosis and Therapy (R Klapdor, Ed) Zuckschwerdt Verlag Munchen · Bern · San Francisco; pp 293-296, 1990.
6. Tempero MA. Carcinoma of the Pancreas. In: Current Therapy in Oncology, JF Foley and JM Vose (Eds), WB Saunders; pp 57-62, 1994.
7. Tempero MA. General Application of Monoclonal Antibodies. In: Current Therapy in Oncology, JF Foley and JM Vose (Eds), WB Saunders; pp 399-402, 1994.
8. Tempero MA and Rasmussen B. Upper Gastrointestinal Cancer. In: Current Cancer Therapeutics, J. M. Kirkwood, M. T. Lotze and J. M. Yasko (eds), Current Medicine publisher; pp 91-104, 1994.
9. Tempero MA. Tumor of the Pancreas. In: American College of Gastroenterology 1995 Annual Postgraduate Course Syllabus, EMM Quigley, Course Director and BA Lashner and ML Schiffman, Course Co-Directors; pp 365-378, 1995.
10. Tempero MA and Rasmussen B. Upper Gastrointestinal Cancer. In: Current Cancer Therapeutics - Second Edition, J.M Kirkwood, M. T. Lotze, and J.M Yasko (eds), Churchill Livingstone publisher developed by Current Medicine; pp 128-143, 1996.
11. Tempero MA and Colcher DC. Radiolabeled Monoclonal Antibodies: Therapy of Solid Tumors. In: Encyclopedia of Cancer, JR Bertino (ed), Academic Press, Inc.; vol III pp. 1448-1458, 1997.
12. Tempero MA. Update on the Medical Management of Advanced Colon Cancer. In: Progress in Anti-Cancer Chemotherapy, D Khayat and G Hortobagyi (eds), Blackwell Science, Inc; pp. 149-160, 1997.
13. Tempero MA. Chemotherapy of Pancreatic Cancer. In: Advances in Pancreatic Cancer, H Reber (ed), Humana Press, Totowa, NJ, pp 265-280, 1998.
14. Tempero MA, Vaziri IA, and Rasmussen B. Upper Gastrointestinal Cancer. In: Current Cancer Therapeutics - Third Edition, J.M Kirkwood, M. T. Lotze, and J.M Yasko (eds), Churchill Livingstone publisher developed by Current Medicine, pp 137-155, 1998.
15. Tempero MA. Biological Approaches to the Therapy of Pancreatic Cancer. In: Pancreatic Disease: State of the Art and Future Aspects of Research, PG Lankisch and EP DiMagno (eds), Springer-Verlag Berlin Heidelberg New York, pp 221-229, 1998.
16. Brand RE and Tempero MA. Carcinoma of the Pancreas.. In: Current Therapy in Oncology - 2nd Edition, JF Foley, JM Vose, and JO Armitage (Eds), WB Saunders, pp 74-80, 1999.
17. Tempero MA. Biologic Therapy of Gastrointestinal Cancer. In: Gastrointestinal Oncology, AB Benson III (ed), Kluwer Academic Publishers, Norwell, MA, pp 227-237, 1999.

18. Tempero M. Advances in the Management of Pancreatic Cancer. In: Progress in Anti-Cancer Chemotherapy, GN Hortobagyi and D Khayat (Eds), Springer-Verlag France, Berlin, Heidelberg, pp 295-304, 1999.
19. Yeo, C, Abrams, R, Tempero, M. Pancreas Cancer: Clinical Management. In: Principles and Practice of Gastrointestinal Oncology, Lippincott, Williams, & Wilkins, Baltimore, MD. 2001.
20. Dollinger, M, Rosenbaum, E, Tempero, M. Everyone's Guide to Cancer Therapy, Somerville House Books Limited, 2001.
21. Ko, A, Dollinger, M, Rosenbaum, E, Tempero, M. Everyone's Guide to Cancer Therapy, Andrews McMeel Publishing, LLC, 5th Edition Wong D. 2008.
22. Tempero, M., Kern, S., Conley, B., Pancreatic Cancer: An Agenda for Action: Report of the Pancreatic Cancer Progress Review Group (PRG). NCI/NIH Publication 01-4940, February 2001.
23. Staveley-O'Carroll, K, Zeh, H, Tempero, M. Upper Gastrointestinal Cancer. In: Current Cancer Therapeutics- 4th Edition, Current Medicine, Inc. Philadelphia, 2001.
24. Tempero, M., Brand, R. Carcinoma of the Pancreas. In: Cecil Textbook of Medicine, Harcourt Health Sciences Companies. Philadelphia, pp 1220-1222, 2004; revised 2006, revised 2009.
25. Tempero, M., Termuhlen, P, Brand, R, McGinn, C. In: Gastrointestinal Oncology - Clinical Aspects and Management of Pancreatic Adenocarcinoma: Management Options: Locally Advanced Unresectable Pancreatic Cancer. Oxford University Press, New York, pp 377-385, 2004.
26. Ko, A., Tempero, M. Monoclonal Antibodies and Other Targeted Therapies. In: Von Hoff DD, Evans DB, and Hruban RH (eds). Pancreatic Cancer. Boston: Jones and Bartlett, 2005.
27. Ko, A., Tempero, M. Pancreatic Cancer: Adjuvant Therapy. In: McCulloch, P., Kerr, D., and Ajani, J. (eds). Gastrointestinal Oncology: Evidence and Analysis. New York: Informa Healthcare USA, Inc., 2007
28. Lillis-Hearne, P., Tempero, M., Koong, A. J. LEIBEL'S TEXTBOOK OF RADIATION ONCOLOGY, Third Edition. Elsevier. Revised 2009.

PATENTS ISSUED OR PENDING (ALLOWED): *None*

OTHER CREATIVE ACTIVITIES

1. Pancreas Cancer News Volume 1 (May 2005), Volume 2 (April 2007), Volume 3 (May 2008), and Volume 4 (July 2009). Produced annually with content and oversight provided by Dr Tempero. Distributed to all Cancer Center members and staff, Program Directors, Pancreas Program Donors and to be posted on the UCSF Medical Center website for pancreatic cancer.
2. UCSF Medical Center pancreatic cancer website was created and launched since last merit

increase 2007. Content development and oversight provided by Dr Tempero. Includes comprehensive patient education on disease, disease management, patient resources and research program overview. This website is accessible to providers, healthcare consumers and the general public. http://www.ucsfhealth.org/adult/medical_services/cancer/pancreatic/

3. The National Comprehensive Cancer Network (NCCN) Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (Versions 2006, 2007, 2008, 2009, 2010). Available at: <http://www.nccn.org>. Dr Tempero is chair of the NCCN Pancreatic Adenocarcinoma Panel which created these guidelines. She provides input for the content and leadership for the overall development of the guidelines. These guidelines are widely distributed across the nation and are accessible to both providers and patients via website and print.

ABSTRACTS:

1. Tempero MA, Foley JF and Kessinger A: VP-16-213 after failure with combination chemotherapy for small cell carcinoma of the lung. Proc ASCO 21:460, 1980.
2. Tempero MA, West W, Zetterman RK: Failure of dietary cellulose fiber to prevent colon tumors in dimethylhydrazine (DMH)-treated rats on high cholesterol diets. Gastroenterology 80:1301, 1981.
3. Tempero MA, Petersen R and Lemon HM: The clinical usefulness of liver scans and liver chemistries in detecting metastatic malignant disease. Proc ASCO 22:C-208, 1981.
4. Tempero MA, West W, and Zetterman RK: The effect of dietary fiber and high cholesterol on colon tumor incidence and size in DMH-treated rats. Proc AACR 22:442, 1981.
5. Tempero MA, West W and Zetterman RK: The protective effect of dietary in the presence of dietary cholesterol in dimethylhydrazine (DMH)-induced colon cancer. Proc AACR 23:276, 1982.
6. Tempero MA, Kessinger A and Lemon HM: Hexamethylmelamine and L-PAM as second-line therapy in ovarian carcinoma. Proc ASCO 1:16, C-450, 1983.
7. Tempero MA and Zetterman RK: The effect of diet on thymidine (3H-TdR)- labeling of colon mucosa in diemthylhydrazine (DMH)-treated rats. Proc AACR 24:97, 1983.
8. Reed E, Tempero MA, Edney J and Foley JF: Disseminated intravascular coagulation (DIC), a complication of peritoneovenous shunts for malignant ascites. Proc ASCO 2:86, C-334, 1983.
9. Tempero MA, Vandewalle C and Anderson J: Sensitivity and specificity of hepatic ultrasound in the diagnosis of liver metastases. Proc ASCO 3:9, C-33, March 1984.
10. Rosenberg M, Tempero MA and Zetterman RK: Local effect of bile on colon crypt cell proliferation. Proc AACR 25:79, 311, March 1984.
11. Zetterman RK, Tempero MA, Baker H, Chen T and Frank O: Anti-Vitamin Therapy May Suppress DMH-Induced Colon Adenocarcinoma Expression. Gastroenterology 86:1307, 1984.
12. Thompson JS, Tempero MA, Haun JL, Vanderhoof JA: The Importance of Luminal Factors in Neomucosal Growth. Gastroenterology 86:1281, 1984.

13. Tempero MA and Graham CL: Effect of Selenium on 3H-TdR Uptake in Colon Tissue. Cell Kinetics Society, 1985.
14. Reed E, Tempero MA, Foley J, Mailliard J and Johnson S: Cisplatin and Vinblastine Therapy in Non-Small Cell Lung Cancer. Proc ASCO 4:187, C-731, 1985.
15. Reed E and Tempero MA: The Effect of Diet on Radiation-Induced Changes in Gastrointestinal Cell Proliferation. Proc AACR 26:68, 269, 1985.
16. Petrie HT, Tempero MA, Klassen LW and Kay HD: Reversible inhibition of human lymphoproliferative response by selenium. FASEB 1985.
17. Tempero MA and Zetterman RK: Failure of bile salt promotion of colon cancer in the absence of the fecal stream. Gastroenterology 87:1612, 1985.
18. Zetterman RK, Tempero MA, Frank O, and Baker H: Vitamin content is increased in experimental rat colon adenocarcinoma. Gastroenterology 87:1642, 1985.
19. Lemon HM, Foley JF, Bresnick E, Kessinger MA, Birt D, Tempero M and Cohen SM: Education in Cancer Prevention. Proc AACR, 1985.
20. Uchida E, Tempero MA, Burnett DA, Pour PM: Correlative Studies on Antigenicity of Pancreatic Cancer and Blood Group Types. ISPO, Copenhagen. November 1985.
21. Tempero MA, Nishioka K, Wolfrey W, Zetterman R. Chemoprevention with Difluoromethylornithine (DFMO) During and After Carcinogen Exposure in Colon Cancer. Proc AACR 27:497, 1986.
22. Pour P, Uchida E, Tempero MA, Burnett DA and Steplewski Z: Blood Group Antigenicity of Induced Pancreatic Cancer. Proc AACR 27:1355, 1986.
23. Tempero MA, Uchida A, Pour PM, Burnett DA, Steplewski Z: Correlation of CA 19-9 Antigen Levels and Tumor Response in Pancreatic Cancer. Proc ASCO 5:51, 1986.
24. Tempero MA, Uchida E, Burnett DA, Pour PM: Relationship between CA 19-9 and Lewis Blood Group Antigen Expression in Pts. with Pancreatic Cancer. Gastroenterology 90:5, 1659. 1986.
25. Tempero MA, Zetterman RK: Long Term Changes in Colon Crypt Cell Proliferation Following Single Dose Dimethylhydrazine (DMH). Gastroenterology 90:5, 1660. 1986.
26. Pour PM, Takasaki H, Uchida E, Tempero MA, Steplewski Z, Metzgar R. Comparative Studies on Pancreatic Cancer Antigen Expression Detected by CA 19-9 and Dupan-2. American Pancreatic Association, 1986.
27. Tempero MA, Uchida E, Takasaki H, Burnett D, Pour PM. CA 19-9 and Lewis Antigen Expression in Pancreatic Cancer. Symposium on Cancer and Smoking Related Diseases, University of Nebraska Medical Center. 1986.
28. Tempero MA, Uchida E, Takasaki H, Burnett D, Hornberger E, Steplewski Z and Pour P. CA 19-9 Levels and Tumor Response in Pancreatic Cancer. Proc of ASCO 6:81 Abst. #316, 1987.

29. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RG and Pour PM. Correlative Study on Expression of CA 19-9 and DU-PAN-2 in Tumor Tissue and in Serum of Patients with Pancreatic Cancer. Proc of AACR 28:355, Abst. #1404, 1987.
30. Sharp JG, Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, and Quaife MA. Detection of metastasis of human colon tumor xenografts in nude mice using radiolabeled monoclonal antibody (MAb) fragments. Clinical Nuclear Medicine 12:32, 1987.
31. Ness MJ, Tempero MA, and Linder J. Immunohistochemistry with B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Modern Pathology 1:66A, 1988.
32. Tempero MA, Colcher D, Takasaki H, Takiyama Y, Schlom J and Pour PM. Comparison of CA 19-9 and TAG 72 expression in pancreatic cancer. American Association for Cancer Research. Proc of AACR 29:385 Abst. #1531, 1988.
33. Tempero MA, Kay HD, Harvey E, Steplewski Z and Klassen L. Enhancement of both Antibody Dependent and Natural Cytotoxic Function in Pancreatic Cancer Patients given Gamma Interferon. Proc of ASCO 7:162 Abst. #624, 1988.
34. Pour PM, Tempero MA, Takasaki H, Uchida E, Takiyama Y, Burnett DA and Joshi SS, Liu C, Bliss KD, Kelly RF, Augustine SC, Crouse DA, Tempero MA, Quaife MA and Sharp JG. Comparison of Methods for Radioiodination of Monoclonal Antibody B72.3. Radiation Research Proceedings, 1988.
35. Tempero MA, Kay HD, Sivinski CL and Klassen L. Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity. Third Nebraska Symposium on Cancer and Smoking Related Diseases. February 1988
36. Lobo F, Vose J, Tempero MA, Kay HD, Sivinski C, Klassen L and Armitage JO. Failure of rIL-2 to induce LAK activity in patients with lymphoma. Proc of ASCO 8:179 Abst. #694, March 1989.
37. Tempero, M, Takasaki H, Metzgar HR and Pour PM. Tumor antigen levels predict survival in pancreatic cancer. American Society of Clinical Oncology. Proc of ASCO 8:113 Abst. #437, March 1989.
38. Haga Y, Tempero MA, Zetterman R and Kay HD. Bilirubin inhibits lymphocyte mitogenesis and interleukin-2 production. Gastroenterology 96:A605, 1989.
39. Herlyn D, Wettendorff M, Iliopoulos D, Tempero MA and Koprowski H. Idiotypic networks in cancer patients treated with monoclonal antibody. Proc of AACR 30:392 Abst. #1557, March 1989.
40. Joshi SS, Liu CN, Bliss KD, Augustine SC, Tempero MA, Crouse DA and Sharp JG. In vivo and in vitro binding of monoclonal antibody B72.3 radiolabeled using different methods. Proc of AACR 30:360 Abst. #1427, March 1989.
41. Lobo F, Tempero MA, Sivinski C, Klassen L and Kay HD. Generation of lymphokine-activated killer cells after cryopreservation of peripheral blood mononuclear cells. Proc of AACR 30:323 Abst. #1279, March 1989.
42. Tempero MA, Haga Y, Sivinski C, Kay D, and Klassen L. Absence of biologic effects with levamisole treatment. ASCO Proc 9:121, Abstr #470, 1990.

43. Kay HD, Haga Y, Uhl B, Egami H, Tempero MA, and Pour P. The Syrian hamster as a preclinical model for pancreatic cancer: in vitro antitumor IL-2-boosted cell-mediated cytotoxicity. AACR Proc 31:248, Abstr #1466, 1990.
44. Haga Y, Siviniski C, Kay HD, Blottiere H, Steplewski Z, Harvey E, and Tempero MA: Biologic responses to high dose murine monoclonal antibody infusions in pancreatic cancer patients. AACR Proc 31:254, Abstr #1501, 1990.
45. Sivinski CL, Tempero MA, Klassen L, and Kay HD. Gamma interferon treatment inhibits interleukin-2 enhancement of natural cytotoxicity. AACR Proc 31:237, Abstr #1404, 1990.
46. Haga Y, Kay HD, Tempero MA, and Zetterman RK. Novel mechanism for inhibition of phytohemagglutinin-induced proliferation in bilirubin-laden human lymphocytes. Gastroenterology, 98:A592, May 1990.
47. Pour PM, Egami H, Chaney W, Tempero MA, Takiyama Y and Kay HD. A preclinical model for diagnosis and therapy of pancreatic cancer. Gastroenterology 98:A231, May 1990.
48. Sharp JG, Joshi SS, Bliss K, and Tempero MA: Amelioration of the hematological toxicity of therapeutic levels of radiolabelled monoclonal antibody B72.3 in mice by bone marrow transplantation. Antibody Immunonconj Pharm 3:49, Abstr #46, 1990.
49. Tempero MA, Mitchell M, Higginbotham P: Tolerance of protracted infusion 5-fluorouracil and oral leucovorin. ASCO Proc 10:1160, Abstr #505, 1991.
50. Sivinski CL, Haga Y, and Tempero MA: Interleukin-2 boosted antibody dependent cellular cytotoxicity using monoclonal antibody 17-1A and pancreatic cancer cell lines. Proc AACR 32:329 Abstr #1361, 1991.
51. Haga Y, Tempero MA, Zetterman R: Impairment of cell-mediated cytotoxicity in bilirubin-laden human lymphocytes. Gastroenterology 100:A749, 1991.
52. Tempero M, Joshi S, Dalrymple G, Augustine S, Harrison K, Holdeman K, Jacobson D, Jackson J, and Colcher D: Myelotoxicity in a phase I trial of radiolabeled monoclonal antibody B72.3. Keystone Symposia on Molecular & Cellular Biology. J Cellular Biochemistry Suppl 16A:192, 1992 Abstr #D210.
53. Tempero M, Berg A, Block M, Hutchins M, Moravec D, and Langdon R: A phase II trial of protracted therapy with 5-Fluorouracil and leucovorin in metastatic colon cancer. ASCO Proc 11:189, 1992 Abstr #571.
54. Sivinski CL and Tempero M: Failure to modulate tumor-associated antigens expression on human pancreatic cancer cell lines by alpha and gamma interferons. AACR Proc 33:302, 1992, Abstr #1799.
55. Joshi SS, Woo DV, Colcher DM, and Tempero M: In vivo internalization of monoclonal antibody 17-1A. AACR Proc 33:346, Abstr #2065, 1992.
56. Tempero MA, Dalrymple G, Colcher D, Joshi S, Quadri S, Linder J, Augustine S, and Leichner P: Cancer Therapy using radioimmunoconjugates: Implications for breast cancer. Pisa Symposia in Oncology Breast Cancer: From Biology to Therapy, 1992.
57. Harrison KA, Dalrymple GV, Leichner PK, Tempero MA, Colcher DM, Augustine SC,

- Bierman PJ, Joshi SS, Holdeman KP, Quadri SM, Schneiderman MH, and Jacobson DA: Clinical radiobiology of radiolabeled antibody therapy. Proc 41st Annual Meeting of the Radiation Research Society, pp 117, ABSTR #23-24, 1993.
58. Tempero MA, Colcher D, Dalrymple G, Harrison K, Augustine S, Schlom J, Linder J, and Leichner P: High dose therapy with ¹³¹I conjugated monoclonal antibody CC49: A phase I trial. Antibody Immunonconj Pharm 6:90, Abstr #84, 1993.
59. Tempero MA, Berg A, Block M, Hutchins M, Moravec D, and Langdon R. A phase II trial of protracted therapy with 5-Fluorouracil and leucovorin in metastatic colorectal cancer. ASCO Proc 12:201, 1993, Abstr #594 (poster).
60. Hansen S, Tempero MA, Sorrel M, Shaw B, Donovan J and Kumar P. Chemoradiotherapy followed by orthotopic liver transplantation (OTLT) for proximal cholangiocarcinoma (ChCA): The UNMC experience. ASCO Proc 12:226, Abstr #695, 1993.
61. Sivinski CL, Joshi SS, Colcher D, and Tempero MA. Interferon- γ modulates the antigen recognized by MAb 17-1A on HT29 colorectal carcinoma cells *in vitro*. Proc AACR 34:455, Abstr #2715, 1993.
62. Joshi SS, Jackson JD, Dalrymple DV, Colcher D and Tempero MA. Bone marrow CFU-GM is predictive of myelosuppression induced by high dose radioimmunoconjugates in intestinal cancer patients. Proc AACR 34:223, Abstr #1334, 1993.
63. Gwilt P, Lear C, Birt D, Tempero M, Grandjean A, Ruddon R, and Nagel D: Modulation of human acetaminophen metabolism by garlic extract. Proc AACR 34:556, Abstr #3313, 1993 (poster presentation).
64. Baranowska-Kortylewicz J, Bierman PJ, Quadri SM, Harrison KA, Lai J, Leichner PK, Holdeman KP, Augustine SC, Schneiderman MH, Tempero MA, Colcher DC, Jacobson DA, Dalrymple GV. Pharmacokinetics and stability of polyclonal antiferritin antibodies (RTAF) in patients with advanced Hodgkin's disease. European Journal of Nuclear Medicine 20:986, Abstr #692, 1993 (oral presentation).
65. Tempero M and Colcher D. An overview of monoclonal-based therapy in pancreatic cancer. Int J Pancreatol 16:300, 1994 (oral presentation).
66. Harrison K, Bierman P, Leichner P, Kortylewicz J, Quadri S, Holdeman K, Augustine S, Tempero M, Colcher D, Lai J, Helseth L, Schmidt B, Capadano M, Jacobson D, Kelly R, Witte R, Schneiderman M, Farnham M, and Dalrymple G: Y Antiferritin for end-stage Hodgkin's disease. Antibody Immunoconj Radiopharm 7:92, 1994 (oral presentation).
67. Tempero M, Capadano M, and Tarassoff P. Dose escalation of Gemcitabine in previously untreated patients with pancreatic adenocarcinoma. Proc Amer Soc Clin Oncol 13:218, Abstr #660, 1994 (poster presentation).
68. Joshi SS, Sivinski CL, Bliss K, Colcher D, Tempero M. Therapeutic efficacy of internalizing ¹²⁵I-labeled monoclonal antibody 17-1A against human colon carcinoma. Proc AACR 35:648, Abstr #3863, 1994 (poster presentation).
69. Tempero M and Capadano M. Maintaining dose intensity of protracted infusion 5-FU with leucovorin in metastatic colorectal cancer. Proc AACR 36:241, Abstr #1434, 1995 (poster

presentation).

70. Tempero M, Hansen S, Enke C, Zetterman R, Donovan J, Shaw B, and Sorrell M. Chemoradiotherapy followed by orthotopic liver transplantation (OLT) for unresectable cholangiocarcinoma (ChCA). Proc ASCO 14:193, Abstr #449, 1995 (poster presentation).
71. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Dalrymple G, and Colcher D. Phase Ia/Ib Clinical Trial of a Radioimmunoconjugate (Yttrium MAb CC49) in patients (pts) with Gastrointestinal Adenocarcinomas. Proc AACR, 37:611, Abstr #4189, 1996 (poster presentation).
72. Tempero, M, Leichner P, Harrison K, Baranowska-Kortylewicz N, Dalrymple G, Augustine S, and Colcher D. The emerging role of radiolabeled antibodies in cancer. Innovative Therapies in Cancer Treatment, Ravenna, Italy, November 25-26, 1995.
73. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Baranowska-Kortylewicz J, Eckblad M, Augustine SC, Tempero MA. Patient-specific dosimetry of IN-111/Y-90-labeled monoclonal antibody CC49. Society of Nuclear Medicine 43rd Annual Meeting 1996.
74. Leichner PK, Lydiatt D, Lydiatt W, Colcher D, Johansson S, Augustine S, Baranowska-Kortylewicz J, Harrison KA, Akabani G, Klein JL, Herpst JM, Hanna MG, and Tempero MA. Therapeutic potential of Yttrium-90 labeled human monoclonal antibody (Y-LiLo-16.88) in patients with head and neck squamous cell cancer. Sixth Conference on Radioimmunodetection & Radioimmunotherapy of Cancer, Tumor Targeting 2:173, 1996.
75. Vose J, Colcher D, Bierman P, Leichner P, Akabani G, Harrison K, Hohenstein M, Lesser S, Hammershaimb L, Goldenberg DM, Tempero M, and Armitage J. Therapy of refractory non-Hodgkin's lymphoma (NHL) with LL2 (anti-CD22) radioimmunotherapy (RIT): Results of a repetitive dosing trial. 38th Annual ASH Meeting, 1996.
76. Tempero M. Development in systemic therapy of pancreatic cancer. Ninth Annual European Cancer Conference, September 14-18. 1997.
77. Okazaki S, Tempero MA, and Colcher D. Combination Radioimmunotherapy and Chemotherapy using ¹³¹I-B72.3 and Gemcitabine. AACR Proc 39:310, Abst #2119, 1998.
78. Copur MS, Matamoros A, Capadano M, Goertzen T, McCowan T, Brand R, Lynch JC, and Tempero M: Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: A phase II trial. 35th Annual Amer Soc Clin Oncol Meeting, ASCO Proc 18:249a, Abst #955, 1999 (poster presentation).
79. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, and Abbruzzese J: Randomized phase II trial of dose intense gemcitabine by standard infusion vs. Fixed dose rate in metastatic pancreatic adenocarcinoma. ASCO Proc 18:273a, Abst #1048, 1999 (poster presentation).
80. Cheng JD, Knox SJ, Tempero M, Weiden PL, Horak ID, Gentner L, Bryan K, Gaffigan S, Shaller C, Adams GP, and Weiner LM: Phase II trial of NR-LU-10 pretargeted delivery of ⁹⁰Yttrium in patients with metastatic colon cancer. Proc ASCO 18:436a, Abst #1679, 1999.
81. Okazaki S, Tempero, M, Colcher, D. Combination radioimmunotherapy and chemotherapy using I-B72.3 and taxol. AACR Proc 40:489, Abst #3231, 1999.

82. Von Hoff D, Cox, J, Tempero M, Eder JP, Eckhardt G, Rowinsky E, Smith S, and MacDonald J: Phase II trial of Irofulven (MGI 114) in Patients with Advanced Pancreatic Cancer who have Progressed on Gemcitabine. 36th Annual American Society of Clinical Oncology Meeting. ASCO Abst # 1219, 2000.
83. Augustine, SC, Tempero, MA, Gobar, LS, Devish, KM, Colcher, DM, Baranowska-kortylewicz, J, Rtar, FJ, Norenberg, JP: Radiolabeling, quality testing and in vitro stability evaluation of I-¹³¹ HuCC49Δ2 Mab. J. of Nucl Med 41: 252P, Abst #1109, 2000.
84. Tempero, MA, MacLean, G, Palmer, M, Meikle, A, Kehoe, M, Longenecker, M. Theratope vaccine in metastatic colorectal cancer: immunogenicity and survival in a dose range study. 37th Annual American Society of Clinical Oncology Meeting, ASCO Abst # 1005, 2001. (oral presentation)
85. Blackstock, A, Tempero, MA, Niedwiecki, D, Hollis, D, Mayer, R, Tepper, J. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. ASCO Proc 20:158a, Abst #627, 2001 (poster presentation).
86. Weitzman, S, Smith, S, Eder, J, Tempero, M, Kaci, S, MacDonald, J. Irofulven monotherapy: impressive phase I and II clinical antitumor activity in heavily treated patients. ASCO Proc 20:83b, Abst #2081, 2001.
87. Ko, A, Renshaw F, Hwang, J, Lu, Y, Abbruzzese J, Brand, R, Tempero, M. Prognostic value of CA19-9 in patients with advanced pancreatic cancer receiving fixed-dose rate gemcitabine. ASCO Proc 22, Abst #1039, 2003.
88. Kulke, M. H., Niedzwiecki D., Tempero, M., Hollis, D. R., Mayer, R. J; Dana-Farber Cancer Institute, Boston, MA; Duke University Durham, NC; University of California, San Francisco, CA A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). ASCO Proc 23:315, Abst. # 4011, 2004.
89. Ko, A. H., Dito, E., Schillinger, B., Venook, A. P., Bergsland, E. K., Allen, J., Tempero, M.; UCSF Comprehensive Cancer Center, San Francisco, CA A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa). ASCO Proc 23:339, Abst. # 4107, 2004.
90. A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, D. Wong, M. A. Tempero A phase II study of bevacizumab (BEV) and erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic adenocarcinoma of the pancreas (PanCa). ASCO GI Cancers Symposium, Abst.# 187, 2007.
91. A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, D. Wong, J. Allen, M. A. Tempero. A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual. ASCO Annual Meeting, Abst. # 4548, 2007.
92. A. H. Ko, J. Scott, M. A. Tempero, J. W. Park Detection and significance of circulating tumor cells (CTC) in patients with metastatic pancreatic cancer (PC) receiving systemic therapy. ASCO Annual Meeting, Abst.# 4596, 2007.

93. E. A. Collisson, D. Das, R. Mori, A. C. Hoffmann, G. E. Kim, R. Hajnal, P. V. Danenberg, J. Cooc, K. D. Danenberg, M. A. Tempero. Use of whole genome expression analysis of pancreatic adenocarcinoma to predict prognosis after surgery. ASCO Annual Meeting, Abst. # 4503, 2008.
94. A. P. Venook, A. H. Ko, M. A. Tempero, J. Uy, T. Weber, M. Korn, E. K. Bergsland Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. ASCO Annual Meeting. Abst #15545, 2008.
95. E. K. Bergsland, A. H. Ko, M. A. Tempero, K. Whittaker, T. Weber, L. Fong, J. W. Park, D. Hanahan, A. P. Venook Phase I trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors. ASCO Annual Meeting, Abst. #15026, 2008.
96. E. K. Bergsland, A. H. Ko, M. A. Tempero, K. Whittaker, T. Weber, L. Fong, J. W. Park, B. M. Yeh, D. Hanahan, A. P. Venook. University of California, San Francisco Phase 1 trial of metronomic cyclophosphamide (CTX), bevacizumab (BV) and imatinib (IM) in patients (pts) with advanced solid tumors. ASCO Annual Meeting, Abst. # 14620, 2008.
97. R. Mori, E. A. Collisson, A. C. Hoffmann, G. E. Kim, H. Shimada, S. Togo, P. V. Danenberg, J. Cooc, K. D. Danenberg, M. A. Tempero. Response Genetics, Inc., University of California, San Francisco. Different pancreatic cancer genomic risk prediction models derived from microdissected and non-microdissected paraffin-embedded tissue. ASCO Annual Meeting Abst. #4622, 2008.
98. A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, W. M. Korn, M. A. Tempero, University of California, San Francisco. A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC). ASCO Annual Meeting Abst. #4516, 2008.
99. A. M. Espinoza, A. H. Ko, A. P. Venook, E. K. Bergsland, K. A. Jones, W. M. Korn, R. K. Kelley, E. Dito, M. Ronayne, M. A. Tempero University of California, San Francisco, San Francisco, CA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; University of Utah Huntsman Cancer Institute; Salt Lake City, UT; University of California, San Francisco, San Francisco, CA. A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC). ASCO GI Cancers Symposium Abst. #202, 2010.

